UCB’s Novartis-partnered investigational small molecule has failed to improve symptoms of Parkinson’s disease in a phase 2a ...

Candid Therapeutics, a new San Diego biotech bent on becoming a leader in the emerging T-cell engager space, has unwrapped ...

Following the apparent elimination of a late-stage gene therapy study last week, Swiss drug juggernaut Roche has confirmed ...

Bristol Myers Squibb has terminated cell therapy pacts with two biotechs amid "ongoing portfolio prioritization efforts” ...

Fluid Biomed has raised $27 million to move forward with the development of its bioabsorbable stent designed to divert blood ...

In the wake of the approval Bristol Myers Squibb’s Cobenfy, it seems that news has ramped up in the schizophrenia space. | In ...

Another of PepGen’s trials has encountered resistance from the FDA, with the regulator now putting the company’s plans to ...

PureTech’s only internal drug program has slowed lung function decline in a phase 2 trial in idiopathic pulmonary fibrosis ...

Foghorn Therapeutics has finally given up on its only wholly-owned clinical-stage candidate after the troubled cancer drug ...

Edgewise Therapeutics’ lead candidate has been shown to reduce levels of a biomarker related to skeletal muscle damage in a ...

Pharming is paying $66.1 million to acquire Swedish biotech Abliva and its phase 2-stage med that the Dutch drugmaker ...

After its eye disease antibody flopped in an FDA-requested clinical trial in late November, Outlook Therapeutics is ...